

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## EQUALITY IMPACT ASSESSMENT

### Acute coronary syndromes

#### 4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)

The impact on equality issues has been assessed during guidance development according to the principles of the NICE equality policy.

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

Two consultees pointed out that ACS due to coronary artery dissection (SCAD) has not been covered. This pathology has a greater incidence in women. It is also far less common than ACS due to atherosclerosis. Management would be different and would require a further literature search on most of the questions considered in this update. In view of the relative rarity of the condition, and the delay this would entail for the rest of the guideline, the GC have added a note acknowledging that the guidance does not apply to SCAD but have not changed any recommendations.

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

None were identified.

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

None identified.

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 4.1, 4.2 and 4.3, or otherwise fulfil NICE's obligations to advance equality?

None identified.

4.5 Have the Committee's considerations of equality issues been described in the final guideline, and, if so, where?

See box 4.1

**Updated by Developer:** Bernard Higgins

**Date:** September 2020

**Approved by NICE quality assurance lead:** Kay Nolan

**Date:** November 2020